Introduction
Materials and methods
Study design
Patients
Treatment
Study outcomes
Statistical analysis
Results
Patients
BMI (kg/m2) | ||||
---|---|---|---|---|
Underweight (< 18.5) (n = 542) | Normal (18.5 to < 25) (n = 4410) | Overweight (25 to < 30) (n = 2167) | Obese (≥ 30) (n = 499) | |
BMI, mean (± SD), kg/m2 | 17.1 (± 1.1) | 22.2 (± 1.7) | 26.9 (± 1.4) | 33.4 (± 3.8) |
Age, years | ||||
Mean (± SD) | 78.1 (± 9.0) | 73.6 (± 9.6) | 71.3 (± 9.6) | 69.5 (± 11.0) |
< 75 | 166 (30.6) | 2209 (50.1) | 1274 (58.8) | 305 (61.1) |
≥ 75 | 376 (69.4) | 2201 (49.9) | 893 (41.2) | 194 (38.9) |
Female sex | 287 (53.0) | 1638 (37.1) | 704 (32.5) | 221 (44.3) |
CrCl, ml/min | ||||
Mean (± SD) | 47.0 (± 18.8) | 63.0 (± 28.5) | 77.5 (± 25.6) | 97.9 (± 36.4) |
< 50 | 341 (62.9) | 1284 (29.1) | 252 (11.6) | 31 (6.2) |
≥ 50 | 195 (36.0) | 3091 (70.1) | 1893 (87.4) | 461 (92.4) |
Unknown | 6 (1.1) | 35 (0.8) | 22 (1.0) | 7 (1.4) |
Comorbidities | ||||
Hypertension | 323 (59.6) | 3195 (72.4) | 1,804 (83.2) | 437 (87.6) |
Diabetes mellitus | 81 (14.9) | 869 (19.7) | 596 (27.5) | 197 (39.5) |
Prior ischemic stroke/TIA | 153 (28.2) | 1032 (23.4) | 421 (19.4) | 100 (20.0) |
Congestive heart failure | 162 (29.9) | 1099 (24.9) | 529 (24.4) | 131 (26.3) |
Hepatic dysfunction | 31 (5.7) | 254 (5.8) | 148 (6.8) | 50 (10.0) |
Type of AF | ||||
Paroxysmal | 197 (36.3) | 1546 (35.1) | 723 (33.4) | 143 (28.7) |
Persistent | 200 (36.9) | 1582 (35.9) | 803 (37.1) | 192 (38.5) |
Permanent | 117 (21.6) | 1041 (23.6) | 552 (25.5) | 141 (28.3) |
Other | 0 (0) | 9 (0.2) | 9 (0.4) | 0 (0) |
Unknown | 28 (5.2) | 232 (5.3) | 80 (3.7) | 23 (4.6) |
CHADS2 score | ||||
Mean (± SD) | 2.3 (± 1.4) | 2.2 (± 1.3) | 2.2 (± 1.3) | 2.3 (± 1.2) |
0 | 58 (10.7) | 450 (10.2) | 137 (6.3) | 16 (3.2) |
1 | 97 (17.9) | 1,031 (23.4) | 606 (28.0) | 121 (24.3) |
2 | 158 (29.2) | 1,330 (30.2) | 682 (31.5) | 156 (31.3) |
3 | 113 (20.8) | 848 (19.2) | 389 (18.0) | 121 (24.2) |
4 | 77 (14.2) | 516 (11.7) | 236 (10.9) | 58 (11.6) |
5 | 34 (6.3) | 197 (4.5) | 89 (4.1) | 23 (4.6) |
6 | 5 (0.9) | 38 (0.9) | 28 (1.3) | 4 (0.8) |
CHA2DS2-VASc score | ||||
Mean (± SD) | 3.8 (± 1.6) | 3.4 (± 1.6) | 3.3 (± 1.6) | 3.5 (± 1.6) |
0 | 7 (1.3) | 123 (2.8) | 56 (2.6) | 7 (1.4) |
1 | 39 (7.2) | 448 (10.2) | 220 (10.2) | 36 (7.2) |
2 | 62 (11.4) | 698 (15.8) | 439 (20.3) | 92 (18.4) |
3 | 123 (22.7) | 1,050 (23.8) | 515 (23.8) | 115 (23.0) |
4 | 130 (24.0) | 1,013 (23.0) | 454 (21.0) | 114 (22.8) |
5 | 102 (18.8) | 629 (14.3) | 270 (12.5) | 81 (16.2) |
6 | 51 (9.4) | 319 (7.2) | 148 (6.8) | 37 (7.4) |
7 | 28 (5.2) | 109 (2.5) | 49 (2.3) | 14 (2.8) |
8 | 0 (0) | 20 (0.5) | 16 (0.7) | 3 (0.6) |
9 | 0 (0) | 1 (< 0.1) | 0 (0) | 0 (0) |
Modified HAS-BLED scorea | ||||
Mean (± SD) | 1.7 (± 0.9) | 1.5 (± 1.0) | 1.4 (± 1.0) | 1.5 (± 1.0) |
0 | 31 (5.7) | 528 (12.0) | 332 (15.3) | 77 (15.4) |
1 | 215 (39.7) | 1,776 (40.3) | 905 (41.8) | 204 (40.9) |
2 | 191 (35.2) | 1,431 (32.4) | 650 (30.0) | 145 (29.1) |
3 | 89 (16.4) | 543 (12.3) | 226 (10.4) | 56 (11.2) |
4 | 12 (2.2) | 120 (2.7) | 46 (2.1) | 16 (3.2) |
5 | 4 (0.7) | 12 (0.3) | 6 (0.3) | 1 (0.2) |
6 | 0 (0) | 0 (0) | 1 (< 0.1) | 0 (0) |
7 | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
8 | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Visit classification | ||||
In-hospital | 172 (31.7) | 768 (17.4) | 271 (12.5) | 66 (13.2) |
Outpatient | 370 (68.3) | 3,642 (82.6) | 1,896 (87.5) | 433 (86.8) |
Treatment period and rivaroxaban dosage
Safety and effectiveness outcomes
BMI (kg/m2) | ||||
---|---|---|---|---|
Underweight (< 18.5) | Normal (18.5 to < 25) | Overweight (25 to < 30) | Obese (≥ 30) | |
Incidence, events per 100 patient-years (95% CI) | ||||
Safety outcome | (n = 542) | (n = 4410) | (n = 2167) | (n = 499) |
Any bleeding | 11.72 (8.33–15.11) | 8.42 (7.47–9.36) | 7.04 (5.82–8.26) | 5.47 (3.23–7.70) |
Major bleeding | 2.19 (0.76–3.62) | 1.87 (1.43–2.30) | 1.71 (1.12–2.31) | 1.63 (0.42–2.84) |
Fatal | 0.24 (0.00–0.72) | 0.11 (0.00–0.21) | 0.32 (0.06–0.58) | 0 (0) |
Critical organ bleeding | 0.73 (0.00–1.55) | 0.85 (0.56–1.14) | 0.96 (0.52–1.41) | 0 (0) |
Intracranial hemorrhage | 0.73 (0.00–1.55) | 0.77 (0.49–1.05) | 0.80 (0.40–1.21) | 0 (0) |
Hemoglobin decrease ≥ 2 g/dl | 0.73 (0.00–1.55) | 0.69 (0.43–0.96) | 0.53 (0.20–0.86) | 1.16 (0.14–2.18) |
Transfusion of ≥ 2 units of packed RBC or whole blood | 0.48 (0.00–1.16) | 0.21 (0.07–0.36) | 0.16 (0.00–0.34) | 0.23 (0.00–0.69) |
All-cause mortality | 10.66 (7.51–13.81) | 1.91 (1.47–2.35) | 1.76 (1.16–2.36) | 0.93 (0.02–1.84) |
Effectiveness outcome | (n = 540) | (n = 4392) | (n = 2161) | (n = 497) |
---|---|---|---|---|
Stroke/non-CNS SE/MI | 3.67 (1.81–5.53) | 1.69 (1.27–2.10) | 1.77 (1.17–2.38) | 1.63 (0.42–2.84) |
Stroke | 2.94 (1.28–4.60) | 1.55 (1.15–1.95) | 1.61 (1.04–2.19) | 1.16 (0.14–2.18) |
Ischemic stroke | 2.20 (0.76–3.64) | 1.07 (0.74–1.40) | 1.07 (0.60–1.54) | 1.16 (0.14–2.18) |
Variablea | Number of events | Proportion (%) | Univariable analysis | Multivariable analysisb | ||||
---|---|---|---|---|---|---|---|---|
HR | 95% CI | p value | HR | 95% CI | p value | |||
Major bleeding | ||||||||
Underweight | 9/542 | 1.66 | 1.15 | (0.57–2.30) | 0.692 | 0.97 | (0.48–1.98) | 0.939 |
Normal | 70/4,410 | 1.59 | 1.00 | Reference | 1.00 | Reference | ||
Overweight | 32/2,167 | 1.48 | 0.92 | (0.61–1.40) | 0.700 | 0.97 | (0.63–1.50) | 0.906 |
Obese | 7/499 | 1.40 | 0.88 | (0.40–1.91) | 0.740 | 0.89 | (0.40–1.97) | 0.772 |
All-cause mortality | ||||||||
Underweight | 44/542 | 8.12 | 5.51 | (3.78–8.01) | < 0.001 | 3.56 | (2.40–5.26) | < 0.001 |
Normal | 72/4,410 | 1.63 | 1.00 | Reference | 1.00 | Reference | ||
Overweight | 33/2,167 | 1.52 | 0.92 | (0.61–1.39) | 0.705 | 1.19 | (0.77–1.83) | 0.427 |
Obese | 4/499 | 0.80 | 0.49 | (0.18–1.33) | 0.161 | 0.74 | (0.27–2.05) | 0.562 |
Stroke/non-CNS SE/MI | ||||||||
Underweight | 15/540 | 2.78 | 2.11 | (1.20–3.70) | 0.009 | 1.64 | (0.90–2.99) | 0.104 |
Normal | 63/4,392 | 1.43 | 1.00 | Reference | 1.00 | Reference | ||
Overweight | 33/2,161 | 1.53 | 1.06 | (0.69–1.61) | 0.800 | 1.19 | (0.76–1.84) | 0.447 |
Obese | 7/497 | 1.41 | 0.97 | (0.44–2.12) | 0.940 | 1.15 | (0.52–2.57) | 0.727 |
BMI (kg/m2) | ||||
---|---|---|---|---|
Underweight (< 18.5) (n = 542) | Normal (18.5 to < 25) (n = 4410) | Overweigh (25 to < 30) (n = 2167) | Obese (≥ 30) (n = 499) | |
Adverse events | 44 | 72 | 33 | 4 |
MedDRA System Organ Classa | ||||
Cardiac disordersb | 12 (2.21) | 13 (0.29) | 8 (0.37) | 1 (0.20) |
Cancerb | 9 (1.66) | 15 (0.34) | 5 (0.23) | 1 (0.20) |
Respiratory disordersb | 8 (1.48) | 12 (0.27) | 5 (0.23) | 0 (0) |
Infectionsb | 5 (0.92) | 14 (0.32) | 2 (0.09) | 2 (0.40) |
General and whole-body disorders | 3 (0.55) | 6 (0.14) | 5 (0.23) | 0 (0) |
Renal disorders | 2 (0.37) | 1 (0.02) | 0 (0) | 0 (0) |
Nervous system disorders | 1 (0.18) | 7 (0.16) | 5 (0.23) | 0 (0) |
Metabolism and nutrition disorders | 1 (0.18) | 4 (0.09) | 1 (0.05) | 0 (0) |
Injury, poisoning, and procedural complications | 1 (0.18) | 3 (0.07) | 1 (0.05) | 0 (0) |
Vascular disorders | 0 (0) | 0 (0) | 2 (0.09) | 0 (0) |